이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

유전성 전신 간질(GGE) 및 결신 발작이 있는 16~75세 대상자를 대상으로 NPT 2042와 위약을 비교하는 연구

2026년 9월 24일 업데이트: NeuroPro Therapeutics, Inc.

유전성 전신 간질(GGE) 및 결신 발작이 있는 16~75세 대상자를 대상으로 NPT 2042와 위약을 평가하는 단일 센터, 이중 맹검, 위약 대조 교차 연구

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.

연구 개요

연구 유형

중재적

등록 (실제)

14

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arkansas
      • Little Rock, Arkansas, 미국, 77205
        • Clinical Trials, Inc. (CTI)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

16년 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Subject is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
  2. Subject is aged 16-75 years at the time of consent/assent
  3. Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
  4. Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
  5. Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.
  6. Subject has normal cognition and no clinically significant abnormalities on neurological examination at screening in the opinion of the Investigator
  7. Subject is in otherwise good health (with the exception of epilepsy), as determined by the investigator, and as documented in the medical history, physical examination, and screening laboratory investigations
  8. Subject has a body mass index (BMI) between 18 and 40 kg/m2 inclusive, at screening
  9. Female subjects of child-bearing potential and all men agree to use of highly effective methods of contraception during the study and for 28 days after last dose of study drug
  10. Subject (and parent/caregiver, if applicable) is able to communicate with the investigator and to understand and comply with all study requirements, including the clinic visit schedule

Exclusion Criteria:

  1. Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.

  2. Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)

  3. Subject has a history of convulsive status epilepticus within the past year.

  4. Subject has a history of surgical intervention for treatment of epilepsy

  5. Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)

  6. Subject has severe intellectual disability, severe autism spectrum disorder, or severe developmental disorder such that the subject cannot consent or assent to participate or cannot cooperate with the study procedures

  7. Female subject who is pregnant or lactating

  8. Subject has any clinically significant laboratory abnormality which, in the opinion of the investigator, will exclude the subject from the study

  9. Subject has an active CNS infection, demyelinating disease, degenerative neurological disease, or any CNS disease deemed to be progressive during the course of the study that may confound the interpretation of the study results

  10. Subject has any clinically significant psychiatric illness, psychological or behavioral problems which, in the opinion of the investigator, would interfere with the subject's ability to participate in the study, including but not limited to the following:

    1. Subject has active suicidal ideation prior to study entry as indicated by a positive response ("yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS)
    2. Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt)
  11. Subject is suffering from clinically significant active liver disease, porphyria or has a family history of severe hepatic dysfunction indicated by abnormal liver function tests greater than three times the upper limit of normal (AST and ALT)

  12. Subject has a DSM-V diagnosis of alcohol or drug abuse, or drug addiction within the past 12 months

  13. Subject has participated in any other trials involving an investigational product or device within 30 days of screening or longer, as required by local regulations

  14. Subject is currently using prohibited medications or products

  15. Subject is unable to complete ingestion of four placebo SGCs with a minimum of eight ounces of water at screening

  16. Subject (and parent/caregiver, if applicable) has daily commitments during the study duration that would interfere with attending all study visits

  17. Positive urine drug test for substance of abuse or illegal recreational substances at screening

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: NPT 2042 80mg

NPT 2042 80mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

위약 비교기: Placebo for NPT 2042 80mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

활성 비교기: NPT 2042 160mg

NPT 2042 160mg BID

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

위약 비교기: Placebo for NPT 2042 160mg

Matching placebo for active comparator

NPT 2042 is a new drug being developed as an anti-seizure treatment

Placebo Comparator

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures
기간: Up to 12 weeks

Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.

Up to 12 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures
기간: Up to 12 weeks

Mean and median across subjects of the within subject difference between NPT 2042 and placebo on absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) average duration.

Up to 12 weeks
Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure
기간: Up to 12 weeks

Mean and median across subjects of the within subject categorical difference in percent change between NPT 2042 and placebo of the frequency of absence seizure (defined as 2.5-6 Hz spike wave bursts lasting greater than 3 seconds) using the following categories:

  • 1 - < 3 seconds
  • 3 - 5 seconds
  • >5 - 10 seconds
  • >10 seconds
Up to 12 weeks
The proportion of NPT 2042- vs. placebo-treated subjects meeting the study specific response criteria
기간: Up to 12 weeks

The proportion of NPT 2042- vs. placebo-treated subjects meeting the following response criteria:

  • ≥50% decrease in endpoint seizure frequency compared to treatment period baseline
  • ≥75% decrease in endpoint seizure frequency compared to treatment period baseline
  • Seizure freedom
Up to 12 weeks
The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)
기간: Up to 12 weeks

The mean change from Baseline across subjects of the within subject difference between NPT 2042 and placebo on the Quality of Life in Epilepsy Questionnaire (QOLIE-31-P)

Up to 12 weeks
The mean change from Baseline in the Digit Symbol Substitution Test
기간: Up to 12 weeks

The mean change from Baseline in the Digit Symbol Substitution Test following treatment with NPT 2042 compared to placebo

Up to 12 weeks
The mean change from Baseline in the Epworth Sleepiness Scale
기간: Up to 12 weeks

The mean change from Baseline in the Epworth Sleepiness Scale following treatment with NPT 2042 compared to placebo

Up to 12 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 11일

기본 완료 (실제)

2026년 8월 17일

연구 완료 (실제)

2026년 9월 23일

연구 등록 날짜

최초 제출

2024년 12월 23일

QC 기준을 충족하는 최초 제출

2025년 1월 7일

처음 게시됨 (실제)

2025년 1월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 24일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NPT 2042 CL-200

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다